June 25, 2024 10:30 AM EDTUpdated 11:32 AM
News Briefing

Zealand Phar­ma aims to raise $900M; Boehringer dis­con­tin­ues three Phase 2 tri­als

ENDPOINTS

Plus, news about Lund­beck, Ot­su­ka, Ju­bi­lant Phar­ma, Fron­tier Med­i­cines, As­traZeneca and Benev­o­len­tAI:

Zealand Phar­ma tar­gets $900M raise: The Dan­ish biotech aims to se­cure the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times